The laminin binding integrin Į6ȕ1 plays a major role in determining the aggressive phenotype of tumor cells during metastasis. Our previous work has shown that cleavage of the Į6ȕ1 integrin to produce the structural variant Į6pȕ1 on tumor cell surfaces is mediated by the serine protease uPA. Cleavage of Į6ȕ1 increases tumor cell motility, invasion, and prostate cancer metastasis, and blockage of uPA inhibits Į6pȕ1 production. In human tumors uPA and uPAR are expressed in tumor cells and tumor associated macrophages (TAMs). TAMs localize to solid tumors and contribute to increased tumor growth and the metastatic phenotype. In our present study, we utilized a co-culture system of PC-3 prostate tumor cells and macrophages (12-Otetradecanoylphorbol-13-acetate (TPA) differentiated human leukemia HL-60 cells) to investigate the hypothesis that macrophages stimulate the production of the pro-metastatic variant Į6pȕ1 on human prostate cancer cells via the uPA/uPAR axis. Our results indicate that adherent macrophages co-cultured with PC-3 cells increased PC-3 uPAR mRNA, uPAR cellsurface protein expression and Į6 integrin cleavage. The stimulation does not require macrophage/tumor cell contact since macrophage conditioned medium is sufficient for increased uPAR transcription and Į6 cleavage dependent PC-3 cell invasion. The increased cleavage was dependent on uPAR since production was blocked by silencing RNA targeting uPAR. These results indicate that macrophages can stimulate uPA/uPAR production in tumor cells which results in Į6 integrin cleavage. These data suggest that tumor associated macrophages promote pro metastatic integrin dependent pericellular proteolysis.
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ABSTRACT:
The laminin binding integrin Į6ȕ1 plays a major role in determining the aggressive phenotype of tumor cells during metastasis. Our previous work has shown that cleavage of the Į6ȕ1 integrin to produce the structural variant Į6pȕ1 on tumor cell surfaces is mediated by the serine protease uPA. Cleavage of Į6ȕ1 increases tumor cell motility, invasion, and prostate cancer metastasis, and blockage of uPA inhibits Į6pȕ1 production. In human tumors uPA and uPAR are expressed in tumor cells and tumor associated macrophages (TAMs). TAMs localize to solid tumors and contribute to increased tumor growth and the metastatic phenotype. In our present study, we utilized a co-culture system of PC-3 prostate tumor cells and macrophages (12-Otetradecanoylphorbol-13-acetate (TPA) differentiated human leukemia HL-60 cells) to investigate the hypothesis that macrophages stimulate the production of the pro-metastatic variant Į6pȕ1 on human prostate cancer cells via the uPA/uPAR axis. Our results indicate that adherent macrophages co-cultured with PC-3 cells increased PC-3 uPAR mRNA, uPAR cellsurface protein expression and Į6 integrin cleavage. The stimulation does not require macrophage/tumor cell contact since macrophage conditioned medium is sufficient for increased uPAR transcription and Į6 cleavage dependent PC-3 cell invasion. The increased cleavage was dependent on uPAR since production was blocked by silencing RNA targeting uPAR. These results indicate that macrophages can stimulate uPA/uPAR production in tumor cells which results in Į6 integrin cleavage. These data suggest that tumor associated macrophages promote pro metastatic integrin dependent pericellular proteolysis.
INTRODUCTION
Chronic inflammation is a major contributor to tumor initiation, progression and metastasis in multiple cancer types including prostate cancer (1-2). The main determinant of patient mortality is the aggressive phenotype of cancer cells, which is dictated by their capacity to invade and metastasize (3) . Inflammatory responses in the solid tumor environment promote tumor metastasis by recruiting migratory immune cells such as macrophages which originate from blood monocytes in the bone marrow. These tumor associated macrophages (TAMs) are attracted from circulation to the tumor due to neoplastic production of inflammatory cytokines and chemokines and will undergo differentiation at the tumor site (4) . Therefore, these specific macrophages are considered to be a tumor educated and tumor specific macrophage (5) (6) . The TAMs can produce various growth factors and cytokines which increase the survival and metastatic capabilities of tumor cells (7) and also directly affect the degradation of the basement membrane surrounding tumor cells by secreting proteases (8) (9) .
The presence of TAMs is correlated with poor patient outcome in aggressive tumors including breast, cervical and bladder cancer (10) . The density, size, and location of tumor infiltrating macrophages in prostate cancer were reported as powerful predictors of patient outcome (11) and prostate cancer specimens harbor increased positive cells expressing the macrophage specific marker CD68 compared to benign glands (12) . More recently, it was demonstrated that expression of macrophage colony-stimulating factor (M-CSF) and its receptor colonystimulating factor-1 receptor (CSF-1R) are increased in primary tumors of patients exhibiting metastatic disease (13) , although other studies have demonstrated variable evidence for TAMs during prostate cancer progression (11) (12) (14) (15) .
The metastatic process during prostate cancer progression is accompanied by significant alterations in the composition of the basement membrane and interactions between extracellular matrix (ECM) proteins and cell surface receptors called integrins. TAMs can affect these interactions dramatically as reviewed by Coussens et al. (1) . Integrins are type 1 transmembrane receptors which bind extracellular matrix proteins including collagens, laminins, fibronectin and vitronectin. In humans, there are currently 18 alpha and 8 beta subunits which form 24 noncovalently associated and unique alpha and beta heterodimers (16) . Previously, we identified that human prostate cancer expresses exclusively laminin receptors (Į3ȕ1, Į6ȕ1 and Į6pȕ1) (17) .
Prostate cancer cell migration and bone metastasis in vivo (18) (19) depends upon the production of a variant form of Į6ȕ1 created by removal of the extracellular binding domain via the serine protease urokinase plasminogen activator (uPA). uPA is a serine protease which converts plasminogen to plasmin by binding with high affinity to either the membrane-bound or soluble urokinase plasminogen activator receptor (uPAR). The urokinase plasminogen activator (uPA) system plays a significant role in promoting cancer invasion and metastasis through regulation of pericellular proteolysis. Recent evidence has demonstrated that uPAR signaling to promote tumor progression is also coordinated by interactions with the integrin family of receptors (20) .
Studies have determined that uPAR is expressed in multiple tumor-associated cell types including the tumor cells and tumor associated stromal cells, neutrophils and macrophages (21) (22) . In prostate cancer, the uPA/uPAR system is associated with prostate cancer metastasis (23) (24) . Recent work by Zhang et al. demonstrates the requirement for stromal uPA and uPAR in promoting prostate tumor growth and macrophage infiltration in vivo (25) .
The goal for this study was to determine whether macrophages induced cleavage of the Į6 integrin to the variant Į6p through activation of the uPA/uPAR system in prostate tumor cells.
To perform these studies we used a co-culture system comprised of prostate tumor cells and the 
MATERIALS AND METHODS
Antibodies and Reagents
The antibody recognizing uPAR used for flow cytometry was a mouse monoclonal (Clone 3/B10, 3936) from American Diagnostica (Stamford, CT). The mouse monoclonal antibody against the c-terminus of uPAR (MAB807) used for immunoblot analysis was from R & D Systems (Minneapolis, MN). The J1B5 rat monoclonal used for immunoprecipitation and flow cytometry analysis which recognizes Į6 was generated by Dr. Caroline H. Damsky. The AA6A rabbit polyclonal recognizing the c-terminus of Į6 used for immunoblot has been previously characterized by our group and was generated and purified by Bethyl Laboratories (Montgomery, TX). The J8H antibody against Į6 has been previously described (19) 
Isolation of Human Monocytes
Human monocytes were isolated from normal donor peripheral blood by mononuclear cell adherence to plastic culture dishes as previously described (26) . Briefly, peripheral blood from a normal donor was diluted 1:1 in RPMI and mixed by gentle inversion. Ficoll was layered on top of the diluted blood in an equal volume. The samples were centrifuged at 400 xg for 40 minutes with slow deceleration at room temperature. The top layer was aspirated and the peripheral blood leukocytes were isolated from the buffy layer and washed with PBS and centrifuged for 3 minutes at room temperature. The cells were cultured in DMEM medium (Invitrogen) supplemented with L-glutamine (2 mM), 10% FBS and penicillin/streptomycin for conditioned medium experiments. Isolated cells were fixed with Fix and Perm reagent according to manufacturer recommendations (Invitrogen) and flow cytometry for CD68 expression was used to identify monocytes. using an anti-CD13-PE antibody diluted 1:100 for detection.
Flow Cytometric Analysis
Immunoprecipitation and Immunoblot Analysis
The Į6 minutes with rotation at room temperature, rinsed in tris-buffered saline with Tween (0.01%) and reacted with actin or tubulin specific antibodies prior to ECL detection.
Quantitative Real-Time RT-PCR
Total RNA was isolated using the RNAEasy Mini Kit (Qiagen, Valencia, CA). Taqman gene expression probes for uPAR (Hs00182181_m1) and GAPDH (Hs99999905_m1) were obtained from Applied Biosystems (Foster City, CA). RT-PCR data was generated using the Taqman One
Step Kit (Applied Biosystems). The REST software program was used to calculate uPAR mRNA levels normalized to GAPDH in each sample. Results include three separate experiments and data are presented as mean ± SD. Statistical analysis was performed using a two-tailed Student's t test.
Silencing RNA Targeting uPAR
The siGENOME silencing RNA (siRNA) smart pool targeting uPAR and a control non-targeting 
Invasion Assay
The tumor cell invasion assay was performed as previously described with slight modifications (19) . Briefly, 50 ȝl of growth factor reduced Matrigel diluted 1:4 with serum free IMDM media was placed in 8.0 micron cell culture inserts (BD Falcon, Franklin Lakes, NJ ) and allowed to solidify for 1 hour at 37°C. The inserts were placed into a 24 well plate with 600 ȝL macrophage Results include three separate experiments performed in quadruplicate and data are presented as mean ± SD. Statistical analysis was performed using a two-tailed Student's t test.
Results
Macrophages stimulated production of the Į6p integrin and uPAR expression in PC-3 prostate tumor cells. Figure 1A illustrates the co-culturing method for TPA differentiated HL- (Fig. 1C) .
These results correlated with increased PC-3 uPAR expression at 24 (3.0 fold), 48 (5.7 fold) and 72 hours (4.5 fold) (Fig. 1D) .
Macrophages increased PC-3 prostate tumor cell surface uPAR expression. Cleavage of the Į6 integrin to Į6p is a cell surface event (29) (30) (31) . Therefore, we next determined whether increased total cell uPAR resulted in increased cell surface expression of the receptor. Flow cytometric analysis indicated an increased number of PC-3 cells expressing cell surface uPAR ( Fig. 2A ) when compared to PC-3 cells cultured alone (Fig. 2B) . Results from three independent experiments represented by Fig. 2A and 2B are graphically depicted in Fig. 2E (Fig. 3B right panel) . Results in Fig. 3C demonstrate that conditioned macrophage medium increased uPAR mRNA expression 2. not induce uPAR expression (Fig. 4A ) or Į6p production (Fig. 4B ). These results demonstrate that uPAR is required for macrophage induced cleavage of integrin Į6.
Macrophages increased Į6p dependent PC-3 tumor cell invasion
We next asked whether TPA differentiated HL-60 macrophages or human monocytes increased Į6p dependent tumor cell invasion. The PC-3 tumor cells were applied to Matrigel-coated inserts to determine if invasion was increased in response to macrophage conditioned medium. PC-3 cell invasion through Matrigel was increased by 66% in response to conditioned medium from TPA differentiated HL-60 cells when compared to undifferentiated HL-60 cell conditioned medium, and by 93% when compared to IMDM medium supplemented with 10% FBS (Fig.   5A ). PC-3 invasion was increased by 93% in the presence of human monocyte conditioned medium when compared to control medium (Fig. 5B) . Increased PC-3 cell invasion in response to macrophage or human monocyte conditioned medium was inhibited by 81% and 54%, respectively, when the prostate cells were treated with the Į6 cleavage blocking antibody J8H ( Fig. 5A and B) . It is intriguing that a subpopulation of PC-3 cells exists which does not exhibit increased uPAR expression in response to macrophages (Figure 2A ). This demonstrates differential regulation of tumor cell responses to macrophages and may be a useful clue for determining whether an aggressive macrophage responsive phenotype exists in prostate cancer patients. cleavage impeded prostate tumor cell invasion in response to macrophages. This antibody does not affect cell adhesion (59) . Therefore, these results highlight a novel mechanism by which a tumor specific modification of a cell surface receptor induced by the stromal environment can be targeted to halt invasive progression of this disease.
In summary, we have identified that macrophages increased uPAR and Į6p integrin on PC-3 cells and Į6p on DU-145 cells. The role of the uPA in Į6p formation to promote prostate cancer cell migration, invasion and metastasis to bone (17, 19, 29, 31) has been established. Reagents developed in our laboratory have demonstrated that this cleavage event and Į6 integrin dependent tumor cell migration and metastasis are inhibited when this function of the receptor is blocked (19, 60) . Here, we demonstrate that tumor associated macrophages directly contribute to an invasive tumor cell phenotype by modulating Į6p through the uPA receptor, uPAR.
Identifying contributing factors in the tumor microenvironment which modulate this cleavage event on tumor cells is necessary for determining alternative therapeutic targets for a multimodality approach to inhibit the invasion steps of metastasis. Inhibition of tumor associated macrophages combined with specific blockade of integrin cleavage and uPAR will be essential for controlling metastatic spread in prostate cancer. 
